Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1--1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)

Gilead Sciences, Inc. (Nasdaq: GILD) today shared new results from a post hoc analysis showing that Livdelzi (seladelpar) was associated with high and sustai